

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 September 2023 (07.09.2023)



(10) International Publication Number
WO 2023/165597 A1

(51) International Patent Classification:

C12N 15/864 (2006.01) *A61P 35/00* (2006.01)
A61P 3/10 (2006.01) *A61P 1/16* (2006.01)

(21) International Application Number:

PCT/CN2023/079543

(22) International Filing Date:

03 March 2023 (03.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/079232

04 March 2022 (04.03.2022) CN

(71) Applicant: **EPIGENIC THERAPEUTICS , INC.**
[CN/CN]; 5 Floor, 1 Unit, Building 4, No. 160, Basheng
Road, China (Shanghai) Pilot Free Trade Zone, Pudong
New Area, Shanghai 200131 (CN).

(72) Inventors: **ZHOU, Changyang**; 5 Floor, 1 Unit, Build-
ing 4, No. 160, Basheng Road, China (Shanghai) Pilot Free
Trade Zone, Pudong New Area, Shanghai 200131 (CN).
SUN, Yidi; 5 Floor, 1 Unit, Building 4, No. 160, Basheng
Road, China (Shanghai) Pilot Free Trade Zone, Pudong
New Area, Shanghai 200131 (CN). **MAO, Shaoshuai**; 5
Floor, 1 Unit, Building 4, No. 160, Basheng Road, Chi-
na (Shanghai) Pilot Free Trade Zone, Pudong New Area,
Shanghai 200131 (CN). **PENG, Wenbo**; 5 Floor, 1 Unit,
Building 4, No. 160, Basheng Road, China (Shanghai) Pi-
lot Free Trade Zone, Pudong New Area, Shanghai 200131
(CN).

(74) Agent: **SHANGHAI DIANSHI PARTNERS , P.C.;**
ZHANG, Cheng, Room 103, Bldg 2, 608#, Shengxia Road,
Pudong New Area, Shanghai 201210 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

WO 2023/165597 A1

(54) Title: COMPOSITIONS AND METHODS OF GENOME EDITING

(57) Abstract: This disclosure provides CRISPR/Cas9 based fusion molecules and guide RNAs for use in in vivo targeted reduction or elimination of VEGFA gene products. This disclosure also relates to formulations, methods of production and methods of use thereof.